Loading…
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
•Fractionated compared with single-dose gemtuzumab increased response depth across most AML molecular groups without increasing toxicity.•Older patients with AML receiving fractionated gemtuzumab had improved survival when induction was consolidated by allograft. [Display omitted] Addition of gemtuz...
Saved in:
Published in: | Blood 2023-11, Vol.142 (20), p.1697-1707 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Fractionated compared with single-dose gemtuzumab increased response depth across most AML molecular groups without increasing toxicity.•Older patients with AML receiving fractionated gemtuzumab had improved survival when induction was consolidated by allograft.
[Display omitted]
Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated schedule provides additional benefit to a single dose. We randomized 852 older adults (median age, 68-years) with AML/high-risk myelodysplasia to GO on day 1 (GO1) or on days 1 and 4 (GO2) of course 1 induction. The median follow-up period was 50.2 months. Although complete remission (CR) rates after course 1 did not significantly differ between arms (GO2, 63%; GO1, 57%; odds ratio [OR], 0.78; P = .08), there were significantly more patients who achieved CR with a measurable residual disease (MRD) |
---|---|
ISSN: | 0006-4971 1528-0020 1528-0020 |
DOI: | 10.1182/blood.2023020630 |